Infantile spasm Cytokines IL-1beta IL-6 IL-17A IL-2
A B S T R A C T
Purpose: Infantile spasm is an age-dependent epileptic syndrome seen in infancy or early childhood. Although studies have investigated the epilepsy-cytokine relationship, there has been insufficient research into the relation between cytokines and infantile spasm. The purpose of this study was to examine the role of cytokines in the pathogenesis of infantile spasm by investigating cytokine levels before and 1 month after adrenocorticotropic hormone (ACTH) therapy in patients diagnosed with the condition. Method: Twenty patients aged between 1 month and 2 years and diagnosed with infantile spasm at the Karadeniz Technical University Medical Faculty Department of Child Health and Diseases Pediatric Neurology Clinic, Turkey, and 20 healthy children were included in the study. Patients received 11 doses of ACTH on 2 days a week. Levels of TNF-alpha and IL-2, the main cytokines involved in inflammation and recently associated with infantile spasm, and of IL-1beta, IL-6 and IL-17A, associated with epileptic seizures, and serum levels of the IL-17A activator IL-23 were investigated in all patients at the start of treatment and 1 month after completion of treatment. Results: No statistically significant difference was observed between pre-and post-treatment patient group and control group IL-1beta, IL-2, IL-23 or TNF-alpha levels. Pre-treatment IL-6 and IL-17A levels were significantly higher in the untreated patient group compared to the healthy control group (p < 0.001 and p = 0.002). Conclusion: Our study supports the recent idea that IL-6 and IL-17A are cytokines involved in the pathogenesis of infantile spasm.
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and infantile spasm. The purpose of this study was to examine the relation between infantile spasm-type seizures and cytokines and to determine whether, as predicted, cytokines are involved in the pathogenesis.
Materials and methods
Twenty patients aged between 1 month and 2 years presenting to the Karadeniz Technical University Medical Faculty Department of Child Health and Diseases Pediatric Neurology Clinic and diagnosed with infantile spasm and 20 age-and sex-matched healthy children were included in the study. Decimal age, age at onset of spasm, age at diagnosis, sex, characteristics of infantile spasm, pre-, natal and postnatal histories, family history, type of delivery, systemic and neurological examination findings, laboratory findings, cerebral imaging (magnetic resonance imaging -MRI) and electroencephalography (EEG) of all patients were investigated. Electroencephalography was performed using a 64-channel Nihon Kohden EEG device with an international electrode system. EEG was evaluated at the Department of Pediatric Neurology. Infantile spasm was diagnosed on the basis of flexor and extensor spasms recurring several times a day and lasting several seconds, hypsarrhythmia at EEG, and interrupted psychomotor development and/or retardation [8] . Hypsarrhythmia at EEG was defined as diffuse slow waves and suppression-burst findings in the form of spike-multiple spike activity or superimposed 'spike, multiple spike slow wave and subsequent suppression periods' [1] . The etiology of infantile spasm was classified under two main groups, symptomatic and cryptogenic, depending on the identification of a definable cause. Patients receiving corticosteroid derivative therapy in the previous 3 months, with accompanying adrenal or pituitary insufficiency, benign myoclonus of early infancy, tonic reflex seizures of early infancy, benign neonatal sleep myoclonus or benign and severe myoclonic epilepsy were excluded from the study. Patients received a total of 11 doses of ACTH (tetracosactide = Synacthen-Novartis depot vial) therapy on 2 days a week. Patients younger than 12 months received 0.5 mg (25 units) intramuscularly and those older than 12 months received 1 mg (50 units) intramuscularly. The ACTH dose was interrupted if side-effects of ACTH therapy, hyperactivity, hypertension, allergic reactions, infection or hypoglycemia, developed. Patients were divided into five groups based on their clinical response to treatment: complete response, temporary complete response, <50% decrease in spasms, >50% in spasms and no response.
Venous blood specimens were taken from all patients at the beginning and 1 month after completion of treatment in order to measure IL-1beta, IL-2, IL-6, IL-17a, IL-23, TNF-alpha levels. Specimens were centrifuged at 3000 rpm for 15 min for serum separation and were then stored at
aside for IL-1beta, IL-2, IL-6, IL-17a, IL-23 and TNF-alpha measurements were thawed at room temperature and studied using ELISA on the same day. The results were compared with those of a healthy age-and sex-matched control group. The control group was established following permission for additional blood collection from the families of healthy children of appropriate age attending our hospital's General Pediatric Department for checkup purposes and scheduled for blood tests. Approval for this was granted by the Karadeniz Technical University Faculty of Medicine ethical committee. The study data were analyzed on SPSS (Statistical Package for the Social Sciences, version 20, SSPS Inc., Chicago, Ill, USA) software. Constant variables were expressed as 'mean AE standard deviation.' The Shapiro-Wilk test was used to determine compatibility with normal distribution of constant variables in the data set. The 't test for dependent groups' was used to compare normally distributed constant variables and the 't test for independent groups' to compare independent variables. The 'Wilcoxon signed ranks test' was used to compare non-normally distributed dependent constant variables and the 'Mann Whitney U test' to compare independent constant variables. The 'chi square test' (x 2 ) was used to test the presence of relations between categoric variables. Relations between constant variables were also examined using the 'Spearman rank correlation test.' p values of less than 0.05 were considered significant for all test results.
Results
The etiology of infantile spasm was determined to be symptomatic in 7 (35%) patients and cryptogenic in 13 (65%). Prematurity was present in 1 (14%) of the patients in the symptomatic group, Hypoxic ischemic encephalopathy in 5 (71%) and congenital CMV infection in 1 (14%). EEG was performed at time of diagnosis in all patients. A classic hypsarrhythmia pattern was determined in 12 (60%) and a modified hypsarrhythmia pattern in 8 (40%). Cerebral imaging was performed in all cases. No pathological finding was determined in 13 (65%) cases, while pathological MRI findings (multicystic encephalomalacia, cerebral atrophy, periventricular leukomalacia and hypoxic injury) were identified in 7 (35%).
No significant differences were determined at comparison of pre-and post-ACTH therapy serum IL-23, TNF-alpha, IL-2 and IL1beta levels and those of the healthy control group (Table 1) .
Serum IL-6 levels decreased following ACTH therapy, although this was not statistically significant. However, comparison of patients' pre-treatment IL-6 levels and those of the healthy control group revealed significant elevation in the patient group (p < 0.001) ( Table 1) . Additionally, a significant correlation was determined between a decrease in IL-6 levels and type of infantile spasm. The decrease in IL-6 levels in the cryptogenic group was significantly greater than that in the symptomatic group (p = 0.044). Presence of differences in parameters between the patient and control groups was tested using the Man Whitney U test ( b ) since the data were not normally distributed. Since IL -2 was normally distributed the presence of a difference before and after treatment in the patient group was investigated using the Paired t test ( c ), while other parameters were compared using the Wilcoxon test ( a ) since these were not normally distributed.
No significant difference was determined between pre-and post ACTH therapy IL-17A levels. However, when patients' pre-ACTH therapy IL-17A levels were compared to those of the healthy control group, these were significantly higher in the non-treated group (p = 0.002) ( Table 1) .
In addition, no statistically significant correlations were determined between age, sex, pre-, natal and post-natal characteristics, type of infantile spasm, type of seizure, EEG characteristics and cerebral pathology findings and IL-1beta, IL-2, IL-6, IL17a, IL-23, or TNF-alpha levels.
ACTH therapy was administered to all patients in 11 doses, twice weekly. ACTH therapy-related side-effects developed in only one patient. ACTH therapy was interrupted due to severe edema in the patient's face and extremities, inability to stand and inability to make eye contact. Complete resolution of spasms was observed in 13 (65%) patients following ACTH therapy, relapse after complete resolution in 2 (10%) and no response to medication in 5 (25%).
Discussion
The effectiveness of steroid therapy in infantile spasm and seizures being triggered following viral infections suggests that immunological and inflammatory mechanisms are involved in the pathogenesis [9] . Our aim in this study was to investigate the levels of IL-1beta, IL-2, IL-6, IL-17a, IL-23, and TNF-alpha, which are known or thought to be associated with epilepsy, in patients with infantile spasm. When we compared pre-and postnatal cytokine levels in patients with infantile spasm with those of the healthy control group, we determined significant elevation in IL-6 and IL-17A levels in the pre-treatment group compared to the healthy control group.
Inflammatory processes in the brain are known to play a role in the pathophysiology of seizures and epilepsy [10] . IL-1beta, TNFalpha and IL-6 produced from monocytes and lymphocytes are also secreted in small amounts in brain tissue, and their levels rise with the occurrence of seizures [11] . In addition, IL-2 has been shown to induce seizures and to lead to recurrent seizure activity in animal models [12] . It also contributes to the inflammatory process by increasing the release of IL-17A, IL-6 and IL-1beta, which have recently begun attracting attention in the context of the pathogenesis of epilepsy [13] . The release of IL-17A and IL-6 is known to increase with IL-23 stimulation [14] . IL-2 levels of the patients with infantile spasm in our study were higher than those of the control group. However, no statistically significant difference was observed between IL-2 levels. Sousa et al. showed an increase in IL-1b and IFN-g levels by investigating IL-1b, IL-5, IL-10, TNF-b and IFN-g levels in CSF specimens from four patients with infantile spasm, three symptomatic and one from the cryptogenic group, aged 4-12 months [15] . Liu et al. reported significantly higher IL-2 and TNF-alpha levels in patients with West syndrome compared to a healthy control group. In another study involving 23 patients with infantile spasm they reported significant elevation in serum IL-2, TNF-alpha and IFN-a levels compared to a healthy control group [16] .
When patients' pre-treatment IL-6 levels were compared with the healthy control group in our study, these were significantly higher in the pre-treatment patient group (p < 0.001). In addition, a significant correlation was determined between a decrease in IL-6 levels and type of infantile spasm. The decrease in IL-6 levels in the cryptogenic group was significantly greater than that in the symptomatic group (p = 0.044). IL-6 is one of the main proteins regulating the organism's immunological response [17] . Although it is principally manufactured by Th 2 cells, it is also secreted by monocytes and macrophages, together with IL-1 and TNF-a [18] . It is also released by astrocytes and microglia as a localized inflammatory response in the brain and causes an inflammatory effect in the CNS. High IL-6 levels are generally determined in neurotropic viral infections in pathologies of the CNS [18] . Studies have reported significant elevation in IL-6 levels in serum and CSF in tonic clonic seizures, and this is thought to vary depending on the seizure area of diffusion and duration [19] . In a study of 12 patients with infantile spasm, Tekgü l et al. compared patients' CSF IL-6 levels with those of a control group with post-traumatic seizure or intracranial infection, but determined no significant findings in terms of these levels [20] . Shiihara et al. compared peripheral lymphocyte and serum cytokine levels before and after ACTH therapy in patients with infantile spasm. They determined low pre-ACTH CD3, CD4 and CD4/CD8 levels and high pretreatment IL-1 beta, IL-5, IL-6, IL-12, IL-15, IFN-gamma, IL-1Ra, exotoxin and macrophage inflammatory protein levels, decreasing after treatment [21] .
Comparison of pre-treatment and control group IL-17A levels in our study revealed significantly higher levels in the untreated patient group (p = 0.002). In addition to the previously known Th1 and Th2 cells, a Th17 cell subgroup largely producing IL-17 has recently been described. Th17 cells are involved in defense against extracellular pathogens and in inflammatory diseases. Like IL-17, Th17 cells regulate inflammation by manufacturing cytokines and diversify as a result of the effect of various antigens and cytokines in T cells. IL-17 acts as a bridge between the natural and acquired immune systems. Seizure production or recurring seizures are thought to occur as a response to the process [22] . In a study of 16 patients with tuberous sclerosis, Jiao-Jiang at al. reported increased IL-17 and IL-17R in the cortical lesions of patients with focal cortical dysplasia. In addition to refractory seizures, infantile spasm-type seizure was identified in 4 patients [23] . Mao et al. reported significantly higher IL-17A levels in patients with epilepsy compared to a healthy control group [24] . There is insufficient information regarding the relation between infantile spasm and IL-17A in the literature. In addition to contributing to the literature, our study also suggests that further more detailed studies concerning IL-17A are now needed to illuminate the pathogenesis of infantile spasm.
Infantile spasm may cause severe neurological sequelae by affecting patients' mental, motor, psychological and emotional development, in addition to refractory seizures, and may have fatal consequences. We think that clinical and laboratory studies will elucidate the mechanism by which infantile spasm develops and assist with the development of etiology-specific treatment models, and that only in this way can the morbidity and mortality of infantile spasm be reduced to a minimum. Our study supports the idea that immune and inflammatory processes are involved in the pathophysiology of infantile spasm.
Limitations of this study include the low patient number and the fact that several factors affect interleukin levels. Based on clinical observation of an increased risk of seizure in periods of infection, we think that cytokines occupy an important place in the pathophysiology of epilepsy and hope that our study will assist future wider studies with larger patient numbers.
